Published in J Biol Chem on August 15, 1985
The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol (1986) 4.16
Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J Cell Biol (1988) 2.72
In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization. J Cell Biol (1987) 1.70
A detailed structural model of cytotactin: protein homologies, alternative RNA splicing, and binding regions. Proc Natl Acad Sci U S A (1989) 1.42
A detailed consideration of a principal domain of vertebrate fibrinogen and its relatives. Protein Sci (1992) 1.31
The primary fibrin polymerization pocket: three-dimensional structure of a 30-kDa C-terminal gamma chain fragment complexed with the peptide Gly-Pro-Arg-Pro. Proc Natl Acad Sci U S A (1997) 1.26
Disulfides modulate RGD-inhibitable cell adhesive activity of thrombospondin. J Cell Biol (1992) 1.23
Characterization of the gene for mp20: a Drosophila muscle protein that is not found in asynchronous oscillatory flight muscle. J Cell Biol (1989) 1.14
Isolation, sequence, and developmental profile of a brain-specific polypeptide, PEP-19. Proc Natl Acad Sci U S A (1986) 1.07
A protease-sensitive site in the proposed Ca(2+)-binding region of human serum amyloid P component and other pentraxins. Protein Sci (1992) 0.90
A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi. J Clin Invest (1989) 0.86
Molecular analysis of scabrous mutant alleles from Drosophila melanogaster indicates a secreted protein with two functional domains. Genetics (1995) 0.85
Tb(III)-ion-binding-induced conformational changes in platelet factor XIII. Biochem J (1989) 0.75
c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A (1997) 5.43
Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med (2000) 5.43
An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol (1990) 4.24
Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem (2000) 3.74
Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A (2000) 3.38
Translocations involving c-myc and c-myc function. Oncogene (2001) 3.21
Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) (1977) 3.20
Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol (1999) 3.08
Max: functional domains and interaction with c-Myc. Genes Dev (1992) 2.88
Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med (1972) 2.79
Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem (2000) 2.70
Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res (2000) 2.62
Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol (1988) 2.60
c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem (1995) 2.47
Therapeutic defibrination in the treatment of thrombotic disease. Lancet (1968) 2.40
The nephrotic syndrome associated with secondary syphilis. An immune deposit disease. Am J Med (1970) 2.37
A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci U S A (1998) 2.34
Participation of cyclin A in Myc-induced apoptosis. Proc Natl Acad Sci U S A (1994) 2.34
A potential transcriptional activation element in the p53 protein. Oncogene (1990) 2.07
Highly sensitive thromboplastins do not improve INR precision. Am J Clin Pathol (1998) 2.03
A comparative analysis of pulmonary perfusion scans with pulmonary angiograms. Am Heart J (1976) 1.93
Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol (1997) 1.92
Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. J Biol Chem (2001) 1.89
Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. Proc Natl Acad Sci U S A (2000) 1.89
Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) (1981) 1.88
Binding and suppression of the Myc transcriptional activation domain by p107. Science (1994) 1.84
Current concepts: guidelines for the use of thrombolytic agents. N Engl J Med (1979) 1.82
Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol (1978) 1.79
The clinical features of submassive and massive pulmonary emboli. Am J Med (1977) 1.77
Letter: Dilantin, agranulocytosis, and phagocytic marrow histiocytes. Ann Intern Med (1976) 1.63
A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol (1995) 1.59
Disseminated intravascular coagulation and portal hypertension following pancreatic islet autotransplantation. Ann Surg (1980) 1.58
Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci U S A (1995) 1.58
Typhoid fever. Studies of blood coagulation, bacteremia, and endotoxemia. Arch Intern Med (1978) 1.52
Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med (1998) 1.51
Inversion of aerotactic response in Escherichia coli deficient in cheB protein methylesterase. J Bacteriol (1986) 1.47
Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann Intern Med (1976) 1.46
Oxidative damage in age-related macular degeneration. Histol Histopathol (2007) 1.44
Acetaminophen and warfarin: undesirable synergy. JAMA (1998) 1.43
c-Myc overexpression uncouples DNA replication from mitosis. Mol Cell Biol (1999) 1.42
Purification and characterization of two isoforms of Acanthamoeba profilin. J Cell Biol (1986) 1.41
Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow. Pharmacogenomics J (2003) 1.41
The effect of arvin on blood coagulation factors. Br J Haematol (1968) 1.39
Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol (1992) 1.39
Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med (1985) 1.38
Transformation by the Bmi-1 oncoprotein correlates with its subnuclear localization but not its transcriptional suppression activity. Mol Cell Biol (1996) 1.36
Identification of a large Myc-binding protein that contains RCC1-like repeats. Proc Natl Acad Sci U S A (1998) 1.34
Oxygen as attractant and repellent in bacterial chemotaxis. J Bacteriol (1987) 1.34
Function of the c-Myc oncoprotein. FASEB J (1992) 1.34
Current status of pulmonary thromboembolic disease: pathophysiology, diagnosis, prevention, and treatment. Am Heart J (1982) 1.34
Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res (1998) 1.33
The hepatitis B virus X protein increases the cellular level of TATA-binding protein, which mediates transactivation of RNA polymerase III genes. Mol Cell Biol (1995) 1.32
Binding and endocytosis of cluster glycosides by rabbit hepatocytes. Evidence for a short-circuit pathway that does not lead to degradation. J Biol Chem (1982) 1.32
Severe liver trauma in the face of coagulopathy. A case for temporary packing and early reexploration. Am J Surg (1982) 1.30
Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res (2000) 1.29
Opposite orientations of DNA bending by c-Myc and Max. Proc Natl Acad Sci U S A (1992) 1.27
Myc target transcriptomes. Curr Top Microbiol Immunol (2006) 1.23
Differential binding of c-Myc and Max to nucleosomal DNA. Mol Cell Biol (1994) 1.19
Disorganization of cultured vascular endothelial cell monolayers by fibrinogen fragment D. Science (1985) 1.19
Amino acid analysis by HPLC: optimized conditions for chromatography of phenylthiocarbamyl derivatives. Anal Biochem (1986) 1.18
Association of methionyl-tRNA synthetase with detergent-insoluble components of the rough endoplasmic reticulum. J Cell Biol (1983) 1.17
The upstream stimulatory factor binds to and activates the promoter of the rat class I alcohol dehydrogenase gene. J Biol Chem (1991) 1.17
The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med (1979) 1.16
Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells. Oncogene (1997) 1.15
MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res (1997) 1.15
Microscopic method for assaying F cell production: illustrative changes during infancy and in aplastic anemia. Blood (1978) 1.15
Definition of the activities and properties of c-myc required to inhibit cell differentiation. Cell Growth Differ (1990) 1.14
Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor. Biochem Biophys Res Commun (1998) 1.13
Nuclear punctate distribution of ALL-1 is conferred by distinct elements at the N terminus of the protein. Proc Natl Acad Sci U S A (1997) 1.12
Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem (1988) 1.12
Detection and modulation in vivo of helix-loop-helix protein-protein interactions. J Biol Chem (1993) 1.11
A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation. J Biol Chem (2001) 1.08
Carbohydrate structure of human fibrinogen. Use of 300-MHz 1H-NMR to characterize glycosidase-treated glycopeptides. J Biol Chem (1982) 1.07
A link between c-Myc-mediated transcriptional repression and neoplastic transformation. J Clin Invest (1996) 1.06
Disseminated intravascular coagulation. Johns Hopkins Med J (1980) 1.06
Cyclin A links c-Myc to adhesion-independent cell proliferation. J Biol Chem (1995) 1.05
The basic helix-loop-helix protein upstream stimulating factor regulates the cardiac ventricular myosin light-chain 2 gene via independent cis regulatory elements. Mol Cell Biol (1994) 1.04
Acute pancreatitis: a complication of Foley catheter gastrostomy. J Natl Med Assoc (1986) 1.04
Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest (2001) 1.03
Cancer genetics: tumor suppressor meets oncogene. Curr Biol (1999) 1.02
Disseminated intravascular coagulation during heparin therapy. Ann Intern Med (1974) 1.01
B-myc inhibits neoplastic transformation and transcriptional activation by c-myc. Mol Cell Biol (1993) 1.01
Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med (1979) 1.00
Pseudothrombocytopenia: manifestation of a new type of platelet agglutinin. Blood (1973) 1.00
Fibrinogen sialic acid residues are low affinity calcium-binding sites that influence fibrin assembly. J Biol Chem (1989) 1.00
Microwave technology for the rapid thawing of frozen blood components. Am J Clin Pathol (1985) 1.00
Multivariate time series projections of parameterized age-specific fertility rates. J Am Stat Assoc (1989) 0.98
Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection. J Clin Invest (1996) 0.98
Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N Engl J Med (1980) 0.98
Variations in the frequency of fetal hemoglobin-bearing erythrocytes (F-cells) in well adults, pregnant women, and adult leukemics. Johns Hopkins Med J (1975) 0.97
The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man. J Lab Clin Med (1978) 0.96
Metastatic intravagal paraganglioma. Case report and review of the literature. Am J Med (1985) 0.95
The synergistic activity of intra-amniotic prostaglandin F2 alpha and urea in the midtrimester elective abortion. Am J Obstet Gynecol (1974) 0.95
Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria. Ann Intern Med (1985) 0.95
Multienzyme complex of aminoacyl-tRNA synthetases: an essence of being eukaryotic. Biochem J (1986) 0.92
Editorial: Thrombocytopenia occurring during heparin therapy. N Engl J Med (1976) 0.92
Pancytopenia secondary to oxalosis in a 23-year-old woman. Blood (1998) 0.92
Heparin-induced coagulopathy. J Lab Clin Med (1977) 0.91